Soligenix, Inc. — 2018 Form 10-K Summary
Business context and reporting period
Soligenix is a development-stage biopharmaceutical company focused on rare diseases and unmet medical needs. This 10-K covers the fiscal year ended December 31, 2018, with 2017 as the comparable period; the filing does not provide standalone fourth-quarter results. The company reported two segments: BioTherapeutics and Vaccines/BioDefense. It had no approved products and generated no significant product-sales revenue.
Key programs include SGX301 for cutaneous T-cell lymphoma (CTCL), SGX942 for oral mucositis in head and neck cancer, RiVax for ricin exposure, and earlier-stage GI and infectious-disease candidates.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue, primarily government contracts and grants | $5.24 million | $5.43 million |
| Cost of revenue | $4.60 million | $4.31 million |
| Gross profit (margin) | $0.64 million (12%) | $1.12 million (21%) |
| Research and development expense | $6.75 million | $5.51 million |
| General and administrative expense | $2.95 million | $3.21 million |
| Operating loss | $9.06 million | $7.59 million |
| Net loss | $8.90 million | $7.15 million |
| Operating cash used | $7.24 million | $6.51 million |
| Cash and cash equivalents at year-end | $8.98 million | $7.81 million |
| Working capital at year-end | $6.13 million | $6.19 million |
Revenue decreased 4%, while net loss increased 25%, principally reflecting increased spending on the pivotal SGX301 and SGX942 trials. Gross margin fell from 21% to 12%, due to a lower share of reimbursable costs eligible for fixed overhead recovery and the absence of RiVax contract milestone fees received in 2017. Interest income rose to $159,006 from $29,906. The 2017 net loss benefited from a $416,810 state income-tax benefit; no income-tax benefit was recorded in 2018.
Cash increased mainly because of the July 2018 public offering, which generated approximately $8.4 million in net proceeds. The company used $7.24 million in operating cash and reported $4.21 million of current liabilities. The balance sheet lists no debt. Accumulated deficit was $166.17 million. Management estimated approximately $14.6 million of awarded government contract and grant funding remained available, subject to agency options and termination rights.
Material changes, outlook, risks and unusual items
- Pipeline: An independent committee’s October 2018 interim review of the SGX301 Phase 3 trial was positive and recommended enrolling approximately 40 additional subjects; it reported no safety concerns. Final results were expected in Q1 2020. SGX942 Phase 3 enrollment was ongoing; interim analysis was anticipated in Q3 2019 and final results in the first half of 2020.
- Other programs: A RiVax Phase 2 trial was planned for the second half of 2019. Further development of SGX203 and SGX201 depended on additional funding or partnerships. The filing describes RiVax, OrbeShield and SGX943 as pre-commercial candidates, not approved products.
- ThermoVax rights: The University of Colorado license was terminated in October 2018 after a development milestone was missed. Soligenix obtained a sublicense from VitriVax for ricin and Ebola vaccine fields, paid a $100,000 fee, and assumed annual royalty and potential milestone obligations.
- Funding outlook: Management expected current resources, government funding and available at-the-market equity proceeds to meet anticipated needs for at least 12 months from issuance of the financial statements; elsewhere, it projected maintaining current operations through at least March 31, 2020. These expectations depend on spending, funding options and financing availability. Management forecast 2019 R&D spending of about $9.3 million, with approximately $3.3 million expected to be reimbursed by grants and contracts.
- Financing and dilution: The July offering issued 8.93 million common shares and warrants, substantially increasing shares outstanding. At December 31, 2018, 6.30 million warrants and 1.02 million options were outstanding. The company also reported up to $8.5 million of remaining capacity under its FBR at-the-market agreement as of March 20, 2019.
- Key risks: Continued losses, dependence on external capital and discretionary government funding, clinical and regulatory uncertainty, third-party manufacturing and trial reliance, and competition. The company had received a Nasdaq minimum-bid-price deficiency notice and needed to regain compliance by September 9, 2019; it anticipated seeking authority for a possible reverse split.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were effective. The independent auditor issued an unqualified opinion on the financial statements; it was not engaged to opine on internal-control effectiveness.
Important facts for investors to verify
- Subsequent SGX301 and SGX942 trial enrollment, interim findings, safety data and final readouts against the filing’s projected timelines.
- Actual cash burn and whether government awards, contract options and FBR equity capacity support the stated runway; confirm financing needs and potential dilution.
- Nasdaq listing compliance status, any reverse-split action, and the impact of outstanding warrants, options and future share sales.
- Continuity and economics of the VitriVax sublicense, including annual royalties, sub-sublicense terms and milestone payments.